Allergan Recalls Tazorac Gel 0.05% Sample Packs for Content Uniformity Failure
Allergan Sales, LLC is recalling Tazorac (tazarotene) Gel 0.05% sample packs due to failed content uniformity specifications.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries, fitting the criteria for a moderate severity score.
Plain-English summary
Allergan Sales, LLC is recalling Tazorac (tazarotene) Gel 0.05%, 15 x 3.5g sample packs. The recall is being conducted because the product failed content uniformity specifications.
The affected product is identified by Lot # 84126 with an expiration date of FEB/2017. The product was distributed nationwide and in Puerto Rico.
Consumers should stop using the recalled product and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- Tazorac (tazarotene) Gel 0.05%, 15 x 3.5g, sample packs, Allergan Inc, Irvine, CA 92612. UPC 300238335159
- Manufacturer
- Allergan Sales, LLC
- Category
- Drug — Topical Prescription
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 84126
- Exp FEB/2017
Distribution
Part of a larger recall action
This product is one of 2 recalled by Allergan Sales, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Allergan Sales, LLC
See all →- HighKeller Funnel 2 breast implant insertion devices recalled for potential coating defect
FDA (Devices) · 2024-05-08
- ModerateAllergan Recalls 72 Bottles of Combigan Eye Drops for cGMP Deviations
FDA (Drugs) · 2019-04-03
- LowAllergan Recalls Combigan Eye Drops Due to Failed Impurity Specifications
FDA (Drugs) · 2017-11-22
- LowAllergan Recalls Lumigan Bimatoprost Ophthalmic Solution Due to Impurities
FDA (Drugs) · 2017-11-22
- SevereAllergan Recalls Blephamide Ophthalmic Ointment Due to Impurity Failures
FDA (Drugs) · 2017-07-05
Same hazard · content uniformity
See all →- ModeratePreferred Pharmaceuticals Recalls Lidocaine Ointment Due to Content Uniformity Failures
FDA (Drugs) · 2026-10-14
- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- HighOral contraceptive tablets recalled after failing content uniformity specifications
FDA (Drugs) · 2025-10-15
- HighCefixime Oral Suspension Recalled for Failed Content Uniformity Specifications
FDA (Drugs) · 2024-06-26
- SevereFDA Recalls Phenytoin Oral Suspension Due to Content Uniformity Failure
FDA (Drugs) · 2023-12-27
Similar recalls
- SevereAllergan Recalls Tazorac Gel 0.05% Due to Content Uniformity Failures
FDA (Drugs) · 2016-10-19
- ModerateTaro Recalls Lidocaine Ointment for Failed Content Uniformity Specifications
FDA (Drugs) · 2026-09-23
- ModerateAidapak Recalls Tolterodine Tartrate ER Capsules Due to Labeling Error
FDA (Drugs) · 2014-01-29
- ModerateTeva Recalls Testosterone Gel Due to High Out-of-Specification Assay Results
FDA (Drugs) · 2020-11-25
- ModerateApotex Recalls Losartan Potassium Tablets for Blend Uniformity Failure
FDA (Drugs) · 2015-07-15
- ModerateFDA Recalls Estrone USP for Prescription Compounding Due to Stability Data Deficiencies
FDA (Drugs) · 2018-02-28